5. Overview of studies assessing parasitaemia incidence only.
| Study ID | Design | Country | Year | Baseline Incidence | MDA group | Baseline | |||||
| Drug (dose) | Interval | No. of rounds | Population targeted | Coverage | Co‐intervention | ||||||
| Garfield 1983 | BAS | Nicaragua | 1981‐82 | 0.4/1000 | CQ (500 mg/day for 3 days) + PQ (15 mg/day for 3 days) | ‐ | 1 | 2,300,000 | 70‐80% | Larval control | None |
| Simeons 1938 | BAS | India | 1935 | 156/1000 | Ate (300 mg) + Plas (60 mg) | ‐ | 1 | 5650 | 100% | Larval control | None |
| Gabaldon 1959 | BAS | Venezuela | 1956‐57 | 0.4/1000 | Pyr (50 mg) | 1 week | 24 | 111,995 | ND | IRS | IRS |
| Kondrashin 1985 | BAS | India | 1981 | 4/1000 | CQ (600 mg) + PQ (45 mg) | 6 months | 2 | 51,325 | 85% | IRS | IRS |
| Paik 1974b | BAS | Solomon Islands | 1972‐73 | 15/1000 | CQ (300 mg/day for 5 days) + PQ (15 mg/day for 5 days) | 3 months | 3 | 1200 | 90% | None | ‐ |
| Cáceres Garcia 2008 | BAS | Venezuela | 2002‐07 | 22/1000 | CQ (25 mg/kg over 3 days) +PQ (3.5 mg/kg over 7 days) | ‐ | 1 | 22,941 | 77% | None | ‐ |
BAS = Uncontrolled before‐and‐after study; PQ = Primaquine; CQ = Chloroquine; Pyr = Pyrimethamine; Plas = Plasmochin; Ate = Atebrin; ND = Not described; IRS = Indoor Residual Spraying.
†Amongst children only